Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920

Inclusion Criteria:

• Healthy as determined by a responsible study physician based on medical evaluation
• Body weight 40 to 100 kg
• Body mass index 19.0 to 30.0 kg/m2

Exclusion Criteria:

• History of allergy or sensitivity to Shellfish or protein based antigens
• previous immunization with KLH
• previous splenectomy
• History of diagnosed or suspected thromboembolic event or coagulation disorder